| Patient | Yul Brynner |
|---|---|
| Date of birth | 1963-07-11 |
| Identifiers | MRN HR-ML020-SYN; SSN (made up) 000-20-4572 |
| Document date | 2026-10-13 |
| Author | Simon Achterberg, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Cycle 2 review on pembrolizumab. [S]
Mr. Brynner returns three weeks after his first pembrolizumab infusion, for cycle 2. He felt a little more tired for two days after the infusion and has otherwise felt well. He has had no diarrhea, abdominal pain, new cough or breathlessness, rash or itching, headache, dizziness, thirst, or yellowing. He saw the palliative care team two weeks ago and found the conversation about his goals and his worries useful; he is sleeping better. The injection medialization of his left vocal fold a week ago made his voice louder and less breathy, and he has begun light rehearsal with the voice therapist's exercises. He wants to rejoin the tour for a few performances a week next month. He has had no bone pain and has not smoked. His first zoledronic acid dose is today, with the pembrolizumab. [S]
| Element | Detail |
|---|---|
| Tolerance of cycle 1 | Two days of extra tiredness; no immune-related symptoms |
| Palliative care | First visit two weeks ago |
| Voice | Louder after injection medialization a week ago; light rehearsal begun |
| Work | Plans a graded return to the tour next month |
| Bone symptoms | None |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Two days of extra tiredness after the infusion; no fever |
| Respiratory | Positive | Occasional morning dry cough, unchanged; no new breathlessness |
| Gastrointestinal | Negative | No diarrhea, abdominal pain, or blood in the stool |
| Integumentary | Negative | No rash or itching |
| Endocrine | Negative | No headache, dizziness, heat or cold intolerance, or thirst |
| Psychiatric | Negative | Mood steady; sleeping better; no thoughts of self-harm |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeks | Every 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panel | Intravenous route | 2026-09-22 | active | S |
| Zoledronic acid 4 mg in 100 mL intravenous infusion over 15 minutes every 12 weeks, for bone metastases | Every 12 weeks, after calcium and creatinine, with a dental examination done first | Intravenous route | 2026-10-13 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet daily, with calcium from food, while on zoledronic acid | One tablet by mouth daily | Oral route | 2026-10-13 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-13 | Body height | 178 | cm | S |
| 2026-10-13 | Body weight | 72.2 | kg | S |
| 2026-10-13 | Body mass index (BMI) [Ratio] | 22.8 | kg/m2 | S |
| 2026-10-13 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-10-13 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-13 | Heart rate | 76 | /min | S |
| 2026-10-13 | Respiratory rate | 16 | /min | S |
| 2026-10-13 | Body temperature | 36.7 | Cel | S |
| 2026-10-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-13 | Thyrotropin [Units/volume] in Serum or Plasma | 2.4 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-10-13 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2026-10-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-55 U/L | Normal | S |
| 2026-10-13 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 8-48 U/L | Normal | S |
| 2026-10-13 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-10-13 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.7-1.3 mg/dL | Normal | S |
| 2026-10-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 92 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-13 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 2026-10-13 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-10-13 | Hemoglobin [Mass/volume] in Blood | 13.5 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-10-13 | Leukocytes [#/volume] in Blood by Automated count | 7.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-10-13 | Platelets [#/volume] in Blood by Automated count | 270 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-10-13 | Total score [Edmonton Symptom Assessment System] | 12 | {score} | S | ||
| 2026-10-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S |
Vital signs recorded on 2026-10-13; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 72.2 kg |
| Voice | Louder and less breathy; longer phonation time |
| Lungs | Slightly reduced breath sounds at the left apex; no crackles |
| Skin | No rash |
| Mouth | Good dentition; no exposed bone |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notes | active | confirmed | C34.12 | S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983. |
| Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compression | active | confirmed | C79.51 | S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer. |
| Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary window | active | confirmed | J38.01 | S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor. |
| Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosis | active | confirmed | R91.8 | S — Synthetic presenting imaging finding, recorded before the tissue diagnosis. |
| Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco since | active | confirmed | Z87.891 | S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Immune-related adverse event laboratory panel | Before each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicated | Completed today | TSH 2.4, free T4 1.1, ALT 30, AST 27, bilirubin 0.7, glucose 104 (non-fasting); no immune-related adverse event |
| Laboratory | Morning cortisol | At baseline and as indicated by symptoms (ASCO); the CMID lists it before each infusion | Not indicated | Baseline 14.2 was normal, and he has no fatigue, dizziness, low blood pressure, or low sodium suggesting adrenal or pituitary injury; repeated if symptoms appear |
| Laboratory | Blood count, kidney function, and calcium before treatment and before zoledronic acid | Before each cycle and each zoledronic acid dose | Completed today | Hemoglobin 13.5, white cells 7.2, platelets 270, creatinine 0.9 (eGFR 92), calcium 9.4 |
| Imaging | Response assessment imaging | Every 6 to 12 weeks on active systemic therapy | Due | First response CT in about six weeks, nine weeks after starting |
| Examination | Dyspnea and cough assessment | Every visit | Completed today | Occasional morning cough, unchanged; no new breathlessness to suggest pneumonitis |
| Self-management | Smoking status and cessation support | Every visit | Completed today | Former smoker; no tobacco |
| Survey | Distress and symptom screening (NCCN Distress Thermometer, ESAS) | Every visit; at minimum at key transitions | Completed today | ESAS total 12, down from 18; distress thermometer 3 of 10; completed at check-in |
| Survey | Depression and anxiety screening | At least yearly; more often during active treatment | Completed today | PHQ-9 4, item 9 scored 0 |
| Survey | Cancer-related fatigue screening | Every visit | Completed today | Two days of extra tiredness after cycle 1, then back to his usual |
| Examination | Weight and dietary review | Each follow-up | Completed today | 72.2 kg, stable |
| Medication safety | Dental evaluation on a bone-modifying agent | Baseline, then periodically on zoledronic acid or denosumab | Up to date | Baseline examination three weeks ago; routine dental care every six months |
| Referral | Early integrated palliative care | Within eight weeks of diagnosis of advanced cancer | Completed today | First visit two weeks ago, two weeks after diagnosis; follow-up next month |
| Self-management | Voice and work support | As needed | Completed today | Injection medialization a week ago; voice therapy continues; graded return to the tour planned |
| Medication safety | Immunizations per ACIP | Yearly review | Due | Influenza, PCV20, and zoster at the preventive visit in two weeks |
| Medication safety | Chemotherapy-induced peripheral neuropathy | Every visit during and after platinum or taxane | Not indicated | No platinum or taxane |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026)
Follow-up: Pembrolizumab cycle 2 and zoledronic acid today. Preventive visit in two weeks. Cycle 3 in three weeks with the laboratory panel. Response CT about nine weeks after starting. Next scheduled visit 2026-10-27: periodic adult preventive visit. [S]